PDCD1 and neoplasm: Noteworthy advances in cancer immunotherapy were achieved by blocking the PD-1/PD-L1/-L2 immune checkpoint axis, which is believed to rely on the pre-existence of an effective cancer-immunity cycle in which the eradication of the tumor cells is solely restricted by this inhibitory immune checkpoint signaling [41].